DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Geron Corporation
Geron Corporation
GERON CORPORATION (Exact Name of Registrant As Specified in Its Charter)
Lengthened Telomeres Restore Immune System to a Younger State
Michael D. West (1953- ) [1]
Geron Initiates Randomized Phase 2 Clinical Trial of Imetelstat in Breast Cancer
Michael West CV
Geron Corporation
Activated Myeloproliferative Neoplasm and Leukemia Stem Cells
Geron Corporation 2000 Annual Report
Geron Annual Report 2008
US Treats First Patient with Human Embryonic Stem Cells (Update 2) 11 October 2010, by Karin Zeitvogel
Geron Corporation 919 E
Geron Announces Presentation at ECTRIMS/ACTRIMS October 25, 2011 3:38 PM ET Non-Clinical Data Supports Use of GRNOPC1 in Multipl
Commercializing Stem Cell-Based Therapies: Meeting NIH and FDA Requirements by Kalah NIH Andfdarequirements Cell-Based Commercializing Stem a Uchincloss T Herapies
Money and Morals
Dr. Michael West CEO, Biotime (US)
Spine and Spinal Disorders September 05-06, 2018 Auckland, New Zealand
Geron Initiates Clinical Trial of GRN163L in Combination with Paclitaxel and Bevacizumab in Patients with Breast Cancer
Curing Aging Bill Andrews, Ph.D
Top View
Why Regenerative Stem Cell Medicine Progresses Slower Than Expected
Consider Using Diffusion Tensor Imaging in Geron Phase I Trial
Geron Obtains Exclusive License for Deriving Cartilage from Human Embryonic Stem Cells from University of Edinburgh September 13
Telomere Binding Protein Antagonists for Stem Cell Therapy
The Telomerase Template Antagonist GRN163L Alters MDA-MB-231 Breast Cancer Cell Morphology, Inhibits Growth, and Augments the Effects of Paclitaxel
View Annual Report
Geron Corporation Which the Cell Remains Metabolically Active but No Longer Divides
Biotime, Inc. (Exact Name of Registrant As Specified in Its Charter)
2009 Geron Annual Report
Geron Initiates Clinical Trial of Human Embryonic Stem Cell-Based Therapy
GERON CORPORATION (Exact Name of Registrant As Specified in Its Charter)
In Brief Geron Gets Green Light for Human Trial of Es Cell–Derived Product
Geron Corporation, Menlo Park, CA Outline GRNVAC1 and GRNVAC2
Client Alert
1 1 0 2 Annual Report
U.S. Patent Office Upholds Key Human Embryonic Stem Cell Patent
The Telomere Total Solution Program Will Raise a Lifespan Revolution! the Telomere Total Solution Program Will Raise a Lifespan Revolution!
What Is the Potential of Oligodendrocyte Progenitor Cells to Successfully Treat Human Spinal Cord Injury? Robert a Watson1* and Trevor M Yeung2
Geron Forms Collaboration to Investigate GRNOPC1 in Alzheimer's Disease Models
From Stem Cell Therapy to Cancer Treatment Elisha Edwards MHC
Geron Corporation Reports First Quarter 2021 Financial Results and Recent Highlights Imerge Phase 3 Clinical Trial in Myelodyspl
With a Successful History in Developing Blood Plasma Volume